| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and six months ended May 31, 2025 and 2024:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended May 31, |
|
|
|
2025 |
|
|
2024 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,871,719 |
|
|
$ |
7,965,500 |
|
PrepaCyte CB |
|
|
14,436 |
|
|
|
35,834 |
|
Public cord blood banking |
|
|
42,688 |
|
|
|
41,477 |
|
Total net revenue |
|
$ |
7,928,843 |
|
|
$ |
8,042,811 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,652,108 |
|
|
$ |
1,830,453 |
|
PrepaCyte CB |
|
|
4,283 |
|
|
|
10,380 |
|
Public cord blood banking |
|
|
200,148 |
|
|
|
183,917 |
|
Total cost of sales |
|
$ |
1,856,539 |
|
|
$ |
2,024,750 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,646,885 |
|
|
$ |
1,515,506 |
|
PrepaCyte CB |
|
|
3,209 |
|
|
|
18,510 |
|
Public cord blood banking |
|
|
(157,460 |
) |
|
|
(142,498 |
) |
Total operating profit |
|
$ |
1,492,634 |
|
|
$ |
1,391,518 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
183,158 |
|
|
$ |
52,796 |
|
PrepaCyte CB |
|
|
6,944 |
|
|
|
6,944 |
|
Public cord blood banking |
|
|
— |
|
|
|
58 |
|
Total depreciation and amortization |
|
$ |
190,102 |
|
|
$ |
59,798 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
551,126 |
|
|
$ |
329,273 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
551,126 |
|
|
$ |
329,273 |
|
|
|
|
|
|
|
|
|
|
For the six months ended May 31, |
|
|
|
2025 |
|
|
2024 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
15,737,607 |
|
|
$ |
15,771,022 |
|
PrepaCyte CB |
|
|
35,349 |
|
|
|
38,834 |
|
Public cord blood banking |
|
|
124,767 |
|
|
|
85,190 |
|
Total net revenue |
|
$ |
15,897,723 |
|
|
$ |
15,895,046 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
3,353,743 |
|
|
$ |
3,715,019 |
|
PrepaCyte CB |
|
|
11,242 |
|
|
|
35,863 |
|
Public cord blood banking |
|
|
476,142 |
|
|
|
434,336 |
|
Total cost of sales |
|
$ |
3,841,127 |
|
|
$ |
4,185,218 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,889,802 |
|
|
$ |
2,573,225 |
|
PrepaCyte CB |
|
|
10,218 |
|
|
|
(10,918 |
) |
Public cord blood banking |
|
|
(351,375 |
) |
|
|
(349,566 |
) |
Total operating profit |
|
$ |
2,548,645 |
|
|
$ |
2,212,741 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
368,066 |
|
|
$ |
78,675 |
|
PrepaCyte CB |
|
|
13,889 |
|
|
|
13,889 |
|
Public cord blood banking |
|
|
— |
|
|
|
420 |
|
Total depreciation and amortization |
|
$ |
381,955 |
|
|
$ |
92,984 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,046,088 |
|
|
$ |
585,732 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
1,046,088 |
|
|
$ |
585,732 |
|
The following table shows the assets by segment as of May 31, 2025 and November 30, 2024:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
May 31, 2025 |
|
|
November 30, 2024 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
59,213,566 |
|
|
$ |
59,259,451 |
|
PrepaCyte CB |
|
|
60,893 |
|
|
|
138,169 |
|
Public cord blood banking |
|
|
5,163,450 |
|
|
|
5,280,013 |
|
Total assets |
|
$ |
64,437,909 |
|
|
$ |
64,677,633 |
|
|